Usefulness of plasma and apolipoprotein B-depleted serum samples in paraoxonase 1 assessment
Open Access
- 23 September 2025
- journal article
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102274
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (22K07466)
This publication has 44 references indexed in Scilit:
- Paraoxonase 1 and atherosclerosis‐related diseasesBioFactors, 2019
- The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?Atherosclerosis, 2019
- HDL cholesterol: reappraisal of its clinical relevanceClinical Research in Cardiology, 2017
- Paraoxonase 1 (PON1) reduces macrophage inflammatory responsesAtherosclerosis, 2013
- VLDL triglycerides inhibit HDL‐associated paraoxonase 1 (PON1) activity: in vitro and in vivo studiesBioFactors, 2012
- Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch womenAtherosclerosis, 2008
- Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME studyAtherosclerosis, 2008
- Development of an ELISA for myeloperoxidase on microplate: Normal reference values and effect of temperature on specimen preparationClinica Chimica Acta, 2006
- Paraoxonase 1 (PON1) is present in postprandial chylomicronsAtherosclerosis, 2005
- Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholineAtherosclerosis, 2005